Opportunity:
Addressing a Major Unmet Medical Need
Conditions such as diabetic foot ulcers, severe burns, surgical wounds, and traumatic injuries often heal slowly and frequently result in scarring that compromises long-term tissue function.
There are currently no FDA-approved small molecule therapies to treat chronic wounds or reduce scar formation. Each unmet medical need represents a massive market opportunity.
Eluciderm’s approach introduces a new therapeutic strategy by targeting the biological signaling pathways that determine how tissue repairs itself.
By shifting repair toward regenerative restoration, therapies derived from Eluciderm’s platform may have applications across several large medical markets including:
-
chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers
-
burn and trauma injuries
-
surgical complications: wound dehiscence, post-procedural infection and scarring complications
-
primary surgical repair and invasive procedures
-
inhalation injury and pulmonary fibrosis
-
cartilage regeneration
-
unmet oncological targets: leukemia, melanoma
-
cosmesis and tissue regeneration
Each of these areas represents significant unmet medical need and substantial global healthcare cost.
Chronic Wounds
Traumatic Open Soft Tissue Wounds
Scar Treatments
Osteoarthritis
(cartilage regeneration)
2014: $96B (Medicare alone)
2020: >$1B
2023: (predicted) $32B
$34.5 million nationally
$237 million worldwide
$4.8B Global cartilage repair market in 2018
Global $50B by 2034
Cosmetic Surgeries
Global $50B by 2027
The Future of Healing:
A New Standard of Care
Healing Shapes Life After Injury
For many, recovery includes lasting reminders. Scar tissue, reduced mobility, chronic wounds, and the emotional weight that comes with them. Eluciderm points toward a different experience. One where healing is more complete, and the body returns closer to its original state.
This shift has real effects in everyday life.
People recover with greater confidence in their bodies. Surgical patients heal with fewer visible and physical limitations. Individuals living with chronic wounds face fewer complications and less disruption over time.
Because the treatment is topical and portable, care can reach more people, in more places: from hospitals to homes, from urban centers to remote environments, and in conditions where traditional care is not easily available.
Better healing changes how people move through the world. It supports independence, resilience, and long-term well-being.
At scale, this creates a quieter but meaningful shift: less burden on healthcare systems, fewer long-term complications and more people able to return to their lives with strength and continuity.
Eluciderm helps move healing toward restoration, and in doing so, raises the baseline for quality of life.